Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms

Human Genetics

Volumn 126, Issue 4, 2009, Pages 559-565

  Hancox, Robert J ^a   Poulton, Richie ^a   Welch, David ^a   McLachlan, Christene R ^a   Olova, Nelly ^a   Robertson, Stephen P ^a   Greene, Justina M ^b   Sears, Malcolm R ^b   Caspi, Avshalom ^c,d   Moffitt, Terrie E ^c,d   Braithwaite, Antony W ^a,e  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MCMASTER UNIVERSITY   (Canada)

^c DUKE UNIVERSITY   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53;

ADULT; ARTICLE; CELL CYCLE ARREST; CIGARETTE SMOKING; DNA DAMAGE; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTRON; LUNG FUNCTION; MAJOR CLINICAL STUDY; PASSIVE SMOKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPIROMETRY;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; COHORT STUDIES; DNA DAMAGE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350161519     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-009-0704-z     Document Type: Article

References (29)

1. Arif E, Vibhuti A, Deepak D, Singh B, Siddiqui MS, Pasha MAQ (2008) COX2 and p53 risk-alleles coexist in COPD. Clin Chim Acta 397:46-50
2. Bansal A, van den Boom D, Kammerer S, Honisch C, Adam G, Cantor CR, Kleyn P, Braun A (2002) Association testing by DNA pooling: An effective initial screen. Proc Natl Acad Sci USA 99:16871-16874
3. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44:266-270
4. Bojesen SE, Nordestgaard BG (2008) The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7:158-163
5. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602
6. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5:3-8
7. Braithwaite AW, Prives CL (2006) p53: More research and more questions. Cell Death Differ 13:877-880
8. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014
9. Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery CA, Butel JS, Bradley A (1992) Mice deficient for P53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221
10. Dumont P, Leu JI, Della PAIII, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
11. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prevent 9:1037-1042
12. Hancox RJ, Poulton R, Greene JM, Filsell S, McLachlan CR, Rasmussen F, Taylor DR, Williams MJ, Williamson A, Sears MR (2007) Systemic inflammation and lung function in young adults. Thorax 62:1064-1068
13. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El Naggar AK, Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872
14. Lee YL, Chen W, Tsai WK, Lee JC, Chiou HL, Shih CM, Wang YC (2006) Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med 147:228-233
15. Leu JI, Dumont P, Hafey M, Murphy ME, George DL (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:443-450
16. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line P53 mutations in a familial syndrome of breast-cancer, sarcomas, and other neoplasms. Science 250:1233-1238
17. Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: A systematic review and meta-analysis. Mutagenesis 18:377-385
18. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
19. Murphy ME (2006) Polymorphic variants in the p53 pathway. Cell Death Differ 13:916-920
20. Orsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204:1295-1301
21. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199
22. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555
23. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, Sears MR (2002) Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 165:1480-1488
24. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R (2003) A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 349:1414-1422
25. Standardization of Spirometry (1995) 1994 Update. Am J Respir Critical Care Med 152:1107-1136
26. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100
27. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJM, Brandt BW, Slagboom PE, Westendorp RGJ (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40:11-15
28. Vousden KH, Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2:594-604
29. Yu ZK, Geyer RK, Maki CG (2000) MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene 19:5892-5897